Conventional Microneedling vs Microneedling With 5-FU (MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation

Photosensitivity Disorders Clinical Trial

— MMP  

Official title:

Conventional Microneedling Compared to Microneedling Associated With 5-FU Infusion (Microinfusion of Medication Into the Skin - MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02904564
• Other study ID #: 001
• Status: Recruiting
• Phase: Phase 4
• Start date: August 20, 2016
• Est. completion date: January 2020

Study information

• Verified date: July 2019
• Source: Clinica Dermatologica Arbache ltda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether 5-FU infusion (Microinfusion of Medicine Percutaneously - MMP) is effective for Idiopathic Guttate Hypomelanosis (IGH) repigmentation compared to conventional Microneedling. MMP is a procedure done with tattoo devices using medication in place of ink.

Description:

Split body design. Each upper limb will receive a different intervention (experimental or placebo)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 2020
• Est. primary completion date: January 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• Healthy males and females, between ages 30 and 70

• Photodamaged skin on upper limbs with IGH lesions meeting aforementioned criteria and excluding differential diagnosis

• Fitzpatrick skin types III - V

• Apt and willing to comply with the entire program as well as appointments, treatment and examination

• Capable of understanding and providing a written informed consent

• Fertile women will have to use a viable birth control method for at least 3 months prior to entry and throughout the entire study

Exclusion Criteria:

• Pregnancy, intention to become pregnant during the course of the study, less than 3 months after delivery or less than 6 weeks after breastfeeding cessation.

• Uncontrolled comorbidity or any disease that, in the investigator's opinion, may interfere with the treatment, healing or cure.

• Present symptoms of hormonal disturbances, as per the investigator's criteria.

• Constitutional photosensitivity or due to metabolic disfunction, or due to use of external agentes (pharmaco, natural products, etc.) prior to initial treatment or during the study.

• Use of oral isotretinoin 6 months prior to initial treatment or during the course of the study.

• Prior treatment in target área 3 months prior to initial treatment or during the course of the study.

• Adverse reaction to any external agentes (gel, lotions or anesthetic creams) required during the study in case no alternative is available for such agent.

• History of keloids or other type of hypertrophic scar formation or poor wound healing in a previously injured area of skin.

• History of collagen disease.

• Displastic nevus or suspicious carcinogenic lesion in área to be treated.

• Hemmorragic disorder or under anticoagulant medication, including the use of aspirin not permitting a minimum 10-day suspension prior to each treatment period (in accordance with the criteria of the patient's physician).

• Skin frailty of sensitivity, favoring hemmorrage.

• History of immunosuppresion / immunological deficiency disorders (including HIV infection) or use of immunosuppressant medication.

• Participation in a study involving medication or another device three months prior to the study or during enrollment herein.

• Any condition which, in the investigator's opinion, would jeopardize the study or its participants, such as acute psychiatric disorders, panic syndrome or any aversion to needles or to the procedure.

• Hypochromiant dermatoses such as vitiligo, pitiriasis, versicolor, albinism.

• Dermatoses that evolve like Koebner's phenomenon.

• Cutaneous infectious process at the application site.

Related Conditions & MeSH terms

• Hypopigmentation
• Photosensitivity Disorders

Intervention

Drug:
• MMP with 5-FU
MMP with 5-FU using tattoo device
• MMP with Saline infusion
MMP with saline infusion using tattoo device

Locations

Country	Name	City	State
Brazil	Clinica Dermatologica Arbache Ltda	São José Dos Campos	SÃO Paulo

Sponsors (1)

Lead Sponsor	Collaborator
Clinica Dermatologica Arbache ltda

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lesions counting of Idiopathic Guttate Hypomelanosis (IGH)	Two assessors will independently count the number of lesions in the treated skin area	30 days
Secondary	Patient satisfaction assessed by Likert scale	self-administered	30 days
Secondary	Local adverse events	Frequency of patients presenting at least one local adverse event (ex:intense pain, scars, infection)	30 days
Secondary	Systemic adverse events	Frequency of patients presenting at least one systemic adverse event (anaphylactic reaction)	24 hours